China Biopharmaceuticals Holdings, Inc.
China Biopharmaceuticals Holdings, Inc., a prominent player in the biopharmaceutical industry, is headquartered in China (CN) and operates extensively across various regions. Founded in the early 2000s, the company has achieved significant milestones, establishing itself as a leader in the development and production of innovative biopharmaceutical products. Specialising in the research, manufacturing, and distribution of therapeutic drugs, China Biopharmaceuticals focuses on areas such as oncology, infectious diseases, and autoimmune disorders. Its unique portfolio includes monoclonal antibodies and recombinant proteins, which are designed to address unmet medical needs. With a strong market position, China Biopharmaceuticals Holdings has garnered recognition for its commitment to quality and innovation, contributing to advancements in healthcare both domestically and internationally. The company continues to expand its influence, striving to improve patient outcomes through cutting-edge biopharmaceutical solutions.
DitchCarbon Score
How does China Biopharmaceuticals Holdings, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
China Biopharmaceuticals Holdings, Inc.'s score of 20 is lower than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
China Biopharmaceuticals Holdings, Inc., headquartered in CN, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments to address carbon emissions at this time. As a current subsidiary, China Biopharmaceuticals Holdings, Inc. may inherit climate-related initiatives and targets from its parent organisation. However, no specific data or targets have been cascaded from the parent company, which limits the available information on their climate commitments. In the broader context of the biopharmaceutical industry, companies are increasingly recognising the importance of sustainability and are often encouraged to adopt science-based targets to mitigate climate impact. Without specific emissions data or reduction initiatives, it remains unclear how China Biopharmaceuticals Holdings, Inc. aligns with these industry trends.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | |
|---|---|---|
| Scope 1 | 533,000,000 | 000,000 |
| Scope 2 | - | 000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
China Biopharmaceuticals Holdings, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
